News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,767 Results
Type
Article (13893)
Company Profile (102)
Press Release (253772)
Multimedia
Podcasts (49)
Webinars (11)
Section
Business (88147)
Career Advice (473)
Deals (15359)
Drug Delivery (67)
Drug Development (36632)
Employer Resources (49)
FDA (6311)
Job Trends (6209)
News (150400)
Policy (14067)
Tag
Academia (442)
Accelerated approval (2)
Adcomms (6)
Allergies (41)
Alliances (23301)
ALS (39)
Alzheimer's disease (402)
Antibody-drug conjugate (ADC) (54)
Approvals (6357)
Artificial intelligence (127)
Autoimmune disease (9)
Automation (5)
Bankruptcy (150)
Best Places to Work (4371)
BIOSECURE Act (9)
Biosimilars (59)
Biotechnology (40)
Bladder cancer (23)
Brain cancer (18)
Breast cancer (103)
Cancer (778)
Cardiovascular disease (81)
Career advice (414)
Career pathing (12)
CAR-T (27)
CDC (3)
Cell therapy (97)
Cervical cancer (5)
Clinical research (31149)
Collaboration (408)
Compensation (184)
Complete response letters (17)
COVID-19 (765)
CRISPR (27)
C-suite (159)
Cystic fibrosis (42)
Data (858)
Denatured (15)
Depression (13)
Diabetes (88)
Diagnostics (1334)
Digital health (1)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (66)
Drug pricing (77)
Drug shortages (12)
Duchenne muscular dystrophy (47)
Earnings (32520)
Editorial (14)
Employer branding (4)
Employer resources (44)
Events (37953)
Executive appointments (450)
FDA (6862)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (256)
Gene editing (45)
Generative AI (9)
Gene therapy (112)
GLP-1 (368)
Government (1319)
Grass and pollen (3)
Guidances (77)
Healthcare (3572)
Huntington's disease (5)
IgA nephropathy (16)
Immunology and inflammation (41)
Immuno-oncology (2)
Indications (18)
Infectious disease (801)
Inflammatory bowel disease (59)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (58)
Interviews (61)
IPO (5901)
IRA (30)
Job creations (2053)
Job search strategy (378)
Kidney cancer (7)
Labor market (17)
Layoffs (188)
Leadership (4)
Legal (3440)
Liver cancer (19)
Lung cancer (108)
Lymphoma (67)
Machine learning (4)
Management (16)
Manufacturing (191)
MASH (39)
Medical device (1292)
Medtech (1294)
Mergers & acquisitions (9706)
Metabolic disorders (293)
Multiple sclerosis (25)
NASH (14)
Neurodegenerative disease (29)
Neuropsychiatric disorders (10)
Neuroscience (618)
NextGen: Class of 2025 (1588)
Non-profit (606)
Now hiring (10)
Obesity (167)
Opinion (126)
Ovarian cancer (25)
Pain (65)
Pancreatic cancer (25)
Parkinson's disease (51)
Partnered (7)
Patents (141)
Patient recruitment (36)
Peanut (12)
People (29141)
Pharmaceutical (64)
Pharmacy benefit managers (13)
Phase I (8108)
Phase II (13178)
Phase III (11828)
Pipeline (622)
Policy (87)
Postmarket research (1401)
Preclinical (3258)
Press Release (25)
Prostate cancer (58)
Psychedelics (8)
Radiopharmaceuticals (123)
Rare diseases (191)
Real estate (2639)
Recruiting (17)
Regulatory (10238)
Reports (14)
Research institute (568)
Resumes & cover letters (56)
Rett syndrome (1)
RNA editing (4)
RSV (8)
Schizophrenia (42)
Series A (46)
Series B (16)
Service/supplier (3)
Sickle cell disease (33)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (7)
Startups (1639)
State (2)
Stomach cancer (3)
Supply chain (33)
Tariffs (42)
The Weekly (32)
Vaccines (171)
Venture capitalists (16)
Weight loss (101)
Women's health (8)
Worklife (4)
Date
Today (44)
Last 7 days (205)
Last 30 days (907)
Last 365 days (11426)
2025 (5490)
2024 (12514)
2023 (14265)
2022 (19565)
2021 (20069)
2020 (19038)
2019 (14892)
2018 (11723)
2017 (13896)
2016 (13132)
2015 (15477)
2014 (12425)
2013 (10596)
2012 (11404)
2011 (11931)
2010 (10896)
Location
Africa (314)
Alabama (15)
Alaska (1)
Arizona (59)
Arkansas (3)
Asia (20306)
Australia (2628)
California (2082)
Canada (1036)
China (312)
Colorado (80)
Connecticut (82)
Delaware (75)
Europe (39801)
Florida (404)
Georgia (45)
Idaho (9)
Illinois (232)
India (16)
Indiana (154)
Iowa (1)
Japan (125)
Kansas (62)
Kentucky (15)
Louisiana (2)
Maine (2)
Maryland (302)
Massachusetts (1778)
Michigan (34)
Minnesota (108)
Mississippi (1)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (12)
New Hampshire (6)
New Jersey (906)
New Mexico (7)
New York (617)
North Carolina (439)
North Dakota (2)
Northern California (874)
Ohio (54)
Oklahoma (4)
Oregon (16)
Pennsylvania (505)
Puerto Rico (9)
Rhode Island (10)
South America (503)
South Carolina (4)
Southern California (871)
Tennessee (39)
Texas (274)
United States (8556)
Utah (41)
Virginia (95)
Washington D.C. (38)
Washington State (137)
West Virginia (1)
Wisconsin (21)
267,767 Results for "portola pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
March 24, 2025
·
6 min read
Press Releases
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
March 26, 2025
·
15 min read
Drug Development
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
October 17, 2024
·
5 min read
Regulatory
Kezar’s Lupus Trial Paused After Four Patient Deaths
The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase IIa PORTOLA trial is ongoing.
October 7, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia
June 3, 2025
·
6 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Deals
Portola Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Sale Of Portola Pharmaceuticals, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) to Alexion Pharmaceuticals, Inc. for $18 per share in cash is fair to Portola shareholders.
May 5, 2020
·
1 min read
Policy
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Portola Pharmaceuticals, Inc.
Rowley Law PLLC is investigating potential securities law violations by Portola Pharmaceuticals, Inc. and its board of directors concerning the proposed acquisition of the company by Alexion Pharmaceuticals, Inc. Stockholders will receive $18.00 for each share of Portola Pharmaceuticals stock that they hold.
May 5, 2020
·
1 min read
Business
Former Portola CEO Takes the Helm at T-Cell Cancer Therapy Company
Scott Garland, the former chief executive officer of Portola Pharmaceuticals, will become the next CEO of South San Francisco-based PACT Pharma.
March 5, 2021
·
3 min read
·
Alex Keown
Press Releases
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
May 29, 2025
·
1 min read
1 of 26,777
Next
